Beam Therapeutics Inc. (BEAM) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
BEAM EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
BEAM Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 84.0% | -274.6% | -57.2% |
| 2024 | -478.7% | -654.3% | -593.1% |
| 2023 | 100.0% | -46.7% | -35.1% |
| 2022 | -411.5% | -555.6% | -474.5% |
| 2021 | -347.8% | -757.0% | -714.9% |
Download Data
Export BEAM earnings history in CSV or JSON format
Free sign-in required to download data
Beam Therapeutics Inc. (BEAM) Earnings Overview
As of May 8, 2026, Beam Therapeutics Inc. (BEAM) reported trailing twelve-month net income of -$65M, reflecting +82.3% year-over-year growth. The company earned $-0.63 per diluted share over the past four quarters, with a net profit margin of -57.2%.
Looking at the long-term picture, BEAM's historical earnings data spans multiple years. The company achieved its highest annual net income of -$9M in fiscal 2017.
Beam Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including EDIT (-$160M net income), CRSP (-$569M net income, -16569.8% margin), NTLA (-$413M net income, -609.9% margin), BEAM has comparable earnings metrics. Compare BEAM vs EDIT →
BEAM Earnings vs Peers
Earnings metrics vs comparable public companies
BEAM Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$80M | +78.8% | -$384M | $-0.81 | -57.2% | -274.6% |
| 2024 | -$377M | -184.3% | -$416M | $-4.58 | -593.1% | -654.3% |
| 2023 | -$133M | +54.2% | -$176M | $-1.72 | -35.1% | -46.7% |
| 2022 | -$289M | +22.0% | -$338M | $-4.13 | -474.5% | -555.6% |
| 2021 | -$371M | -90.5% | -$392M | $-5.77 | -714.9% | -757.0% |
| 2020 | -$195M | -148.4% | -$133M | $-5.49 | -810800.0% | -553166.7% |
| 2019 | -$78M | +32.0% | -$75M | $-1.53 | -435144.4% | -417522.2% |
| 2018 | -$115M | -1220.3% | -$46M | $-3.28 | - | - |
| 2017 | -$9M | - | -$9M | $-0.62 | - | - |
See BEAM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BEAM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BEAM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBEAM — Frequently Asked Questions
Quick answers to the most common questions about buying BEAM stock.
Is BEAM growing earnings?
BEAM EPS is $-0.63, with earnings growth accelerating to +82.3%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-65M.
What are BEAM's profit margins?
Beam Therapeutics Inc. net margin is -57.2%, with operating margin at -274.6%. Below-average margins reflect competitive or cost pressures.
How consistent are BEAM's earnings?
BEAM earnings data spans 2017-2025. The accelerating earnings trend is +82.3% YoY. Historical data enables comparison across business cycles.